Andelyn Biosciences, a contract development and manufacturing organization (CDMO) focused on cell and gene therapy, has secured a license agreement with the Broad Institute to incorporate MyoAAV plasmids into its AAV Curator Platform.   Developed by Broad Institute researchers, MyoAAV plasmids produce adeno-associated viruses (AAVs) that exhibit ten times greater efficiency in targeting muscle tissue compared to traditional vectors while simultaneously reducing liver targeting. This enhanced s...